Us Congress 2023-2024 Regular Session

Us Congress House Bill HB6895 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 I
22 118THCONGRESS
33 1
44 STSESSION H. R. 6895
55 To amend the National Defense Authorization Act for Fiscal Year 2023
66 to extend Federal support for bioindustrial manufacturing processes to
77 include support for the manufacturing of certain pharmaceutical ingredi-
88 ents.
99 IN THE HOUSE OF REPRESENTATIVES
1010 DECEMBER22, 2023
1111 Ms. S
1212 LOTKINintroduced the following bill; which was referred to the
1313 Committee on Armed Services
1414 A BILL
1515 To amend the National Defense Authorization Act for Fiscal
1616 Year 2023 to extend Federal support for bioindustrial
1717 manufacturing processes to include support for the man-
1818 ufacturing of certain pharmaceutical ingredients.
1919 Be it enacted by the Senate and House of Representa-1
2020 tives of the United States of America in Congress assembled, 2
2121 SECTION 1. SHORT TITLE. 3
2222 This Act may be cited as the ‘‘Defense Production 4
2323 and Active Pharmaceutical Ingredients Act’’. 5
2424 VerDate Sep 11 2014 00:30 Jan 09, 2024 Jkt 049200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H6895.IH H6895
2525 kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
2626 •HR 6895 IH
2727 SEC. 2. MODIFICATION OF SUPPORT FOR RESEARCH AND 1
2828 DEVELOPMENT OF BIOINDUSTRIAL MANU-2
2929 FACTURING PROCESSES. 3
3030 Section 215(c)(1) of the James M. Inhofe National 4
3131 Defense Authorization Act for Fiscal Year 2023 (Public 5
3232 Law 117–263; 10 U.S.C. 4841 note) is amended by insert-6
3333 ing ‘‘active pharmaceutical ingredients, key starting mate-7
3434 rials for such ingredients,’’ after ‘‘commodity chemicals,’’. 8
3535 Æ
3636 VerDate Sep 11 2014 00:30 Jan 09, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6301 E:\BILLS\H6895.IH H6895
3737 kjohnson on DSK7ZCZBW3PROD with $$_JOB